AstraZeneca Can't Duck $107.5M Patent Loss To Pfizer Unit
A Delaware federal judge on Tuesday refused to upend a jury's determination that AstraZeneca owes $107.5 million in royalty damages for infringing Pfizer-brand cancer treatment patents, rejecting AstraZeneca's arguments that the...To view the full article, register now.
Already a subscriber? Click here to view full article